Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

NCT03316560 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
29
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Beacon Therapeutics